微信小陈
微信小章| 产品名称： | Pseudomonas aeruginosa (Schroeter) Migula |
|---|---|
| 商品货号： | TS154730 |
| Strain Designations： | PGO2330 |
| Isolation： | Sputum sample, human |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | frozen |
| Storage Conditions： | Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section |
| Preceptrol®： | no |
| Type Strain： | no |
| Antibiotic Resistance： | Multidrug-resistant |
| Comments： | This isolate was collected from a sputum sample of a cystic fibrosis patient during a Phase III clinical trial that tested the effectiveness of aerosolized Tobi (Tobramycin). The 1995-1996 clinical trial was conducted by a consortium led by Chiron and later acquired by Novartis AG. |
| Medium： | ATCC® Medium 18: Trypticase Soy Agar/Broth |
| Growth Conditions： | Temperature: 37°C Atmosphere: Aerobic |
| Name of Depositor： | Chiron/Novartis |
| References： | Ramsey BW, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 328(24): 1740-1746, 1993. PubMed: 8497284 Burns JL, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. 27(1): 158-163, 1998. PubMed: 9675470 Burns JL, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179(5): 1190-1196, 1999. PubMed: 10191222 Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest. 120(3 Suppl): 107S-113S, 2001. PubMed: 11555564 Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 121(1): 55-63, 2002. PubMed: 11796432 |